; Neoprobe to Present at Upcoming Investor Conferences
Learning Center
Plans & pricing Sign in
Sign Out

Neoprobe to Present at Upcoming Investor Conferences


DUBLIN, Ohio--(EON: Enhanced Online News)--Neoprobe to Present at Upcoming Investor Conferences in September 2010 a style='font-size: 10px; color: maroon;' href='h

More Info
  • pg 1
									Neoprobe to Present at Upcoming Investor
September 07, 2010 08:03 AM Eastern Daylight Time  

DUBLIN, Ohio--(EON: Enhanced Online News)--Neoprobe Corporation (OTCBB: NEOP), a diversified
developer of innovative oncology surgical and diagnostic products, is planning to provide business and pipeline
updates to the investor community at a series of conferences over the reminder of 2010. The Company will be
represented by David Bupp, CEO & President, and Brent Larson, SVP & CFO, who invite you to join them at the
following confirmed events:

    l   Rodman & Renshaw Annual Global Investment Conference
        September 13, 2010 at 10:00 am ET at the Palace Hotel in New York City
        Live webcast and 90-day archive at: http://www.wsw.com/webcast/rrshq18/neop

    l   Stifel Nicolaus Annual Healthcare Conference 2010
        September 17, 2010 at 10:20 am ET at the Four Seasons Hotel in Boston
        Live webcast and 30-day archive at: http://www.veracast.com/webcasts/stifel/healthcare2010/97305231.cfm

    l   Life Tech Capital Investor Conference
        November 12, 2010 at the Marriott Marquis in Miami
        Webcast and replay details to be announced.

Neoprobe expects to participate in other conferences over the coming months and will update the investment
community as appropriate when more details are available.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting
the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients.
Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer
surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and
radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe’s subsidiary, Cira Biosciences,
Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to
deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and
diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.

Neoprobe Corporation
Brent Larson, 614-822-2330
Sr. Vice President & CFO
Makovsky + Company
Gene Marbach, 212-508-9645
Permalink: http://eon.businesswire.com/news/eon/20100907005163/en/Brent-Larson/CEO/CFO

To top